In the experimental autoimmune myasthenia gravis (EAMG) model, inhibiting IL-17 activity can significantly alleviate disease symptoms and reduce the level of anti-acetylcholine receptor (AChR) IgG. The gene discussed is IL17A; the disease is myasthenia gravis.